Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect

Cancer Gene Therapy

Volumn 15, Issue 8, 2008, Pages 535-542

  Peled, M ^a,b,c   Shaish, A ^a,b   Greenberger, S ^a,b   Katav, A ^b   Hodish, I ^a,b   Ben Shushan, D ^b   Barshack, I ^a,b   Mendel, I ^a   Frishman, L ^a,b   Tal, R ^a,b   Bangio, L ^a   Breitbart, E ^a   Harats, D ^a,b  

^a Vascular Biogenics Ltd   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adenovirus; Angiogenesis; Apoptosis; Doxorubicin; Fas; Metastasis

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; CASPASE 8; CASPASE 8 INHIBITOR; CASPASE 9; CASPASE 9 INHIBITOR; DEATH RECEPTOR; DOXORUBICIN; GREEN FLUORESCENT PROTEIN; PREPROENDOTHELIN 1; PROTEIN FAS C; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL VIABILITY; CHIMERA; CONTROLLED STUDY; COW; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME INDUCTION; GENE EXPRESSION; LUNG METASTASIS; METASTASIS INHIBITION; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CASPASE 8; CASPASE 9; CATTLE; CELLS, CULTURED; DOXORUBICIN; ENDOTHELIUM, VASCULAR; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC;

ADENOVIRIDAE; MUS;

EID: 48249155476     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.20     Document Type: Article

References (30)

1. Sivridis E, Giatromanolaki A, Koukourakis MI. The vascular network of tumours - what is it not for? J Pathol 2003; 201: 173-180.
2. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795-7798.
3. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
4. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579-5588.
5. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death - inducing signaling complex. Cell 1996; 85: 817-827.
6. Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. Blood 2001; 98: 913-924.
7. Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res 1999; 59: 1356-1361.
8. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-2933.
9. Stennicke HR, Jurgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998; 273: 27084-27090.
10. Greenberger S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004; 113: 1017-1024.
11. Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, Ferber S et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther 2001; 8: 819-827.
12. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999; 274: 7987-7992.
13. Lin T, Zhang L, Davis J, Gu J, Nishizaki M, Ji L et al. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 2003; 8: 441-448.
14. Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S et al. In vivo upregulation of CD95 and CD95 L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 2005; 12: 649-658.
15. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115: 207-216.
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
17. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 1999; 6: 1305-1312.
18. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999; 84: 257-265.
19. Kalyanaraman B, Perez-Reyes E, Mason RP. Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta 1980; 630: 119-130.
20. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000; 275: 33585-33592.
21. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 1998; 83: 516-522.
22. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 2000; 102: 572-578.
23. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998; 161: 3936-3942.
24. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, Lopez-Rivas A et al. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277: 10883-10892.
25. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
26. Cowling V, Downward J. Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002; 9: 1046-1056.
27. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605-4610.
28. Boehm T, Folkman J, Browder T, O0Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
29. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-692.
30. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-196.